Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The opening of our 1000th pharmacy in Karnataka marks an important step
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
This launch is part of the company's strategy to expand its nutraceutical portfolio
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Subscribe To Our Newsletter & Stay Updated